Skip to main content
Clinical Trials/EUCTR2013-001685-42-DK
EUCTR2013-001685-42-DK
Active, Not Recruiting
N/A

Changes in coagulation and platelet reactivity in HIV-1 infected patients switching between abacavir and tenofovir containing antiretroviral regimens - TAPAS

Rigshospitalet0 sitesJune 21, 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV
Sponsor
Rigshospitalet
Status
Active, Not Recruiting
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 21, 2013
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • HIV\-1 infected
  • Can understand and sign written informed consent
  • Between 35 and 70 years old at inclusion
  • Received one of the above mentioned antiretroviral regimens continuously \= 6 months
  • HIV RNA \< 400 copies/mL for \= 6 months
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 80
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Receiving anticoagulant therapy, ADP\-receptor inhibitors, aspirin or NSAIDs
  • Previous ischemic heart disease, peripheral atherosclerotic disease or stroke
  • Coagulation disorder (e.g. hemophilia, factor V Leiden mutation)
  • Platelet count \< 150 x 109/L during the past 6 months from inclusion
  • eGFR\<70 during the past 6 months from inclusion
  • HLA\-B\*57:01 positive genotype
  • Hepatitis B or C positive during the past year from inclusion

Outcomes

Primary Outcomes

Not specified

Similar Trials